The other nilotinib Phase II trial (i.e. Georgetown) has released its results.
NPR.ORG article:
"A Cancer Drug For Parkinson's? New Study Raises Hope, Draws Criticism"
npr.org/sections/health-sho...
Research paper (open access):
"Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease A Phase 2 Randomized Clinical Trial"
jamanetwork.com/journals/ja...
Editorial (not open access, but available via ResearchGate if you are a member):
"The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease"